[1]
|
Lam, R.W., et al. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. III. Pharmacotherapy. Journal of Affective Disorders, 117, S26-S43. http://dx.doi.org/10.1016/j.jad.2009.06.041
|
[2]
|
Corya, S.A., et al. (2006) A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, Fluoxetine, and Venlafaxine in Treatment-Resistant Depression. Depression and Anxiety, 23, 364-372.
http://dx.doi.org/10.1002/da.20130
|
[3]
|
Shelton, R.C., Williamson, D.J., Corya, S.A., Sanger, T.M., Van Campen, L.E., Case, M., Briggs, S.D. and Tollefson, G.D. (2005) Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance. The Journal of clinical psychiatry, 66, 1289-1297. http://dx.doi.org/10.4088/JCP.v66n1012
|
[4]
|
Thase, M.E., Corya, S.A., Osuntokun, O., Case, M., Henley, D.B., Sanger, T.M., Watson, S.B. and Dubé, S. (2007) A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry, 68, 224-236.
http://dx.doi.org/10.4088/JCP.v68n0207
|
[5]
|
McIntyre, A. and Gendron, A. (2007) Selective Serotonin Reuptake Inhibitors or Venlafaxine in Patients with Major Depression, Comorbid Anxiety, and Residual Depressive Symptoms: A Randomized, Placebo. Depression and Anxiety, 494, 487-494.
|
[6]
|
Bauer, M., Pretorius, H.W., Constant, E.L., Earley, W.R., Szamosi, J. and Brecher, M. (2009) Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients with Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study. The Journal of Clinical Psychiatry, 70, 540-549.
http://dx.doi.org/10.4088/JCP.08m04629
|
[7]
|
El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R.J., Datto, C., Lindgren, P. and Eriksson, H. (2010) Extended-Release Quetiapine Fumarate (Quetiapine XR) as Adjunctive Therapy in Major Depressive Disorder (MDD) in Patients with an Inadequate Response to Ongoing Antidepressant Treatment: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study. The International Journal of Neuropsychopharmacology, 13, 917-932.
http://dx.doi.org/10.1017/S1461145710000015
|
[8]
|
Rapaport, M.H., et al. (2006) Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. Neuropsychopharmacology, 31, 2505-2513. http://dx.doi.org/10.1038/sj.npp.1301113
|
[9]
|
Keitner, G.I., Garlow, S.J., Ryan, C.E., Ninan, P.T., Solomon, D.A., Nemeroff, C.B. and Keller, M.B. (2009) A Randomized, Placebo-Controlled Trial of Risperidone Augmentation for Patients with Difficult-to-Treat Unipolar, Non-Psychotic Major Depression. Journal of Psychiatric Research, 43, 205-214.
http://dx.doi.org/10.1016/j.jpsychires.2008.05.003
|
[10]
|
Mahmoud, R., Pandina, G.J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C.M., Kujawa, M.J. and Gharabawi-Garibaldi, G.M. (2007) Risperidone for Treatment-Refractory Major Depressive Disorder. Annals of Internal Medicine, 147, 593-602. http://dx.doi.org/10.7326/0003-4819-147-9-200711060-00003
|
[11]
|
Kennedy, S.H., Lam, R.W., Parikh, S.V., Patten, S.B. and Ravindran, A.V. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. Introduction. Journal of Affective Disorders, 117, S1-S2. http://dx.doi.org/10.1016/j.jad.2009.06.043
|
[12]
|
Birmaher, B. and Brent, D. (2007) Practice Parameter for the Assessment and treatment of Children and Adolescents with Depressive Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1503-1526.
http://dx.doi.org/10.1097/chi.0b013e318145ae1c
|
[13]
|
Findling, R.L., et al. (2011) Practice Parameter for the Use of Atypical Antipsychotic Medications in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry.
|
[14]
|
National Institute for Health and Clinical Excellence (2005) Depression in Children and Young People. CG28 (September).
|
[15]
|
McIntyre, R.S. and Jerrell, J.M. (2009) Polypharmacy in Children and Adolescents Treated for Major Depressive Disorder: A Claims Database Study. The Journal of Clinical Psychiatry, 70, 240-246.
http://www.ncbi.nlm.nih.gov/pubmed/19192465
http://dx.doi.org/10.4088/JCP.08m04212
|
[16]
|
Díaz-Caneja, C.M., et al. (2012) Polypharmacy with Antidepressants in Children and Adolescents. The International Journal of Neuropsychopharmacology, 17, 1063-1082.
|
[17]
|
Olfson, M., Blanco, C., Liu, S.M., Wang, S. and Correll, C.U. (2012) National Trends in the Office-Based Treatment of Children, Adolescents, and Adults with Antipsychotics. Archives of General Psychiatry, 69, 1247-1256.
http://www.ncbi.nlm.nih.gov/pubmed/22868273
http://dx.doi.org/10.1001/archgenpsychiatry.2012.647
|
[18]
|
Vitiello, B., Correll, C., van Zwieten-Boot, B., Zuddas, A., Parellada, M. and Arango, C. (2009) Antipsychotics in Children and Adolescents: Increasing Use, Evidence for Efficacy and Safety Concerns. European Neuropsychopharmacology, 19, 629-635. http://www.ncbi.nlm.nih.gov/pubmed/19467582
http://dx.doi.org/10.1016/j.euroneuro.2009.04.008
|
[19]
|
Fountoulakis, K. and Nimatoudis, I. (2004) Off-Label Indications for Atypical Antipsychotics: A Systematic Review. Annals of General Hospital Psychiatry, 3, 4.
|
[20]
|
Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q.V., Pikalov, A.S. and Thase, M.E. (2009) A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder. Psychopharmacology Bulletin, 42, 57-90.
|
[21]
|
Papakostas, G.I., Shelton, R.C., Smith, J. and Fava, M. (2007) Augmentation of Antidepressants with Atypical Antipsychotic Medications for Treatment-Resistant Major Depressive Disorder: A Meta-Analysis. Journal of Clinical Psychiatry, 68, 826-831. http://dx.doi.org/10.4088/JCP.v68n0602
|
[22]
|
Nelson, J. and Papakostas, G. (2009) Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. American Journal of Psychiatry, 166, 980-991.
http://dx.doi.org/10.1176/appi.ajp.2009.09030312
|
[23]
|
Farahani, A. and Correll, C.U. (2012) Are Antipsychotics or Antidepressants Needed for Psychotic Depression? A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy with Combination Treatment. The Journal of Clinical Psychiatry, 73, 486-496. http://dx.doi.org/10.4088/JCP.11r07324
|
[24]
|
Chen, J., Gao, K.M. and Kemp, D.E., (2011) Second-Generation Antipsychotics in Major Depressive Disorder: Update and Clinical Perspective. Current Opinion in Psychiatry, 24, 10-17.
http://dx.doi.org/10.1097/YCO.0b013e3283413505
|
[25]
|
Komossa, K., Depping, A. and Gaudchau, A., (2012) Second-Generation Antipsychotics for Major Depressive Disorder and Dysthymia (Review). Cochrane Database of Systematic Reviews.
|
[26]
|
Garcia-Toro, M., Medina, E., Galan, J.L., Gonzalez, M.A. and Maurino, J. (2012) Treatment Patterns in Major Depressive Disorder after an Inadequate Response to First-Line Antidepressant Treatment. BMC Psychiatry, 12, 143.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3514293&tool=pmcentrez&rendertype= abstract http://dx.doi.org/10.1186/1471-244X-12-143
|
[27]
|
Cohen, D., Bonnot, O., Bodeau, N., Consoli, A. and Laurent, C. (2012) Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis. Journal of Clinical Psychopharmacology, 32, 309-316. http://dx.doi.org/10.1097/JCP.0b013e3182549259
|
[28]
|
Gao, K.M., et al. (2011) Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized. The Journal of Clinical Psychiatry, 72, 1063-1071. http://dx.doi.org/10.4088/JCP.09r05535gre
|
[29]
|
Ormerod, S., McDowell, S.E., Coleman, J.J. and Ferner, R.E. (2008) Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression. Drug Safety, 31, 597-607.
http://dx.doi.org/10.2165/00002018-200831070-00005
|
[30]
|
Kalsekar, I., Wagner, J.-S., DiBonaventura, M., Bates, J., Forbes, R. and Hebden, T. (2012) Comparison of Health-Related Quality of Life among Patients Using Atypical Antipsychotics for Treatment of Depression: Results from the National Health and Wellness Survey. Health and Quality of Life Outcomes, 10, 81.
http://dx.doi.org/10.1186/1477-7525-10-81
|
[31]
|
Christian, R., et al. (2012) Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults. Agency for Healthcare Research and Quality, Rockville.
|
[32]
|
Lev-Ran, S., Aviram, A., Braw, Y., Nitzan, U., Ratzoni, G. and Fennig, S. (2012) Clinical Correlates of Cannabis Use among Adolescent Psychiatric Inpatients. European Psychiatry, 27, 470-475.
http://dx.doi.org/10.1016/j.eurpsy.2011.11.002
|
[33]
|
Brown, E.S., Nejtek, V.A., Perantie, D.C. and Bobadilla, L. (2002) Quetiapine in Bipolar Disorder and Cocaine Dependence. Bipolar Disorders, 4, 406-411. http://dx.doi.org/10.1034/j.1399-5618.2002.02229.x
|
[34]
|
Price, S.A. and Brahm, N.C. (2011) Antipsychotic Treatment of Adolescent Dual Diagnosis Patients. The Journal of Pediatric Pharmacology and Therapeutics, 16, 226-236.
|